FY27 Revenue Growth: 10-15%
Management provided a specific growth range for FY27 revenue, stating 'the growth rate is around 10 to 15% for the next this year 2027'. The CFO confirmed similar growth rate expected for FY28.
BAJAJHCARE / guidance tracker
Keep management guidance in view.
Bajaj Healthcare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 EBITDA Margin: 18-20%
Management guided that margins will maintain 'mid to high teens level' going forward. In response to working capital question, CFO stated 'for FY 27 and 28 what kind of margin profile can we expect to maintain on a beta level 18 to 20%'.
Peptide Facility Revenue: ₹200-300 Cr Peak
When asked about peak revenue from the 250kg peptide plant, management stated 'once we are to a peak and full utilization of plant we can expect anything around 200 to 300 crores of revenue and the margin would be around 18 to 20%'.
Annual Capex: ₹40-50 Crore
Management committed to ongoing capital expenditure: 'the capex will be every year we are allocating around 40 to 50 crores for next every year it will be like 40 to 50 crores capital expenditure'.